[1] Lai CL, Yuen MF. Chronic Hepatitis B—new goals, new treatment. N Engl J Med, 2008,359: 2488-2491.
[2] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版).肝脏,2015,20:915-932.
[3] 周晶. 替诺福韦酯治疗基因型耐药慢性乙型病毒性肝炎患者疗效及安全性研究.杭州浙江大学,2017.
[4] Marcellin P,Gane E, Buti M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet, 2012,381:468-475.
[5] Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med, 2008,359:2442-2455.
[6] European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012, 57:167-185.
[7] Korean Association for the Study of the Liver.KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol, 2012,18:109-162.
[8] Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut, 2011,60:247-254.
[9] 黄明星,李新华,吴元凯,等.替诺福韦单独与联合其他核苷类似物治疗慢性乙型肝炎患者72周疗效比较.中山大学学报(医学科学版),2014,35:520-524.
[10] Chan HL, Shaikh J, Gupta S, et al.Renal function in nucleos(t)ide analog-treated patients with chronic hepatitis B: A systematic literature review and network meta-analysis. Adv Ther, 2016,33:862-875. |
